All In Biotech

Drug Trial Radar · NCT06127407

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jul 9, 2024

Primary completion

Feb 1, 2028

Study completion Nov 26, 2030

Sponsor

Lead sponsor
Servier Bio-Innovation LLCIndustry
Sponsor type
Industry
Collaborators
Institut de Recherches Internationales Servier
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must have radiographic progression/recurrence of disease according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and have received 0 to 2 prior systemic treatment regimens in the advanced/metastatic setting for conventional chondrosarcoma. The primary endpoint is progression-free survival (PFS) in Grades 1 and 2 participants. Key secondary endpoints are PFS in all randomized participants, overall survival (OS) in Grades 1 and 2 participants, and OS in all randomized participants. Participants who meet enrollment criteria will be randomized 1:1 to receive oral ivosidenib 500mg once daily, or a matching placebo once daily.

Conditions

  • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

Interventions

  • Ivosidenib 500mgDrug

    Provided as tablets, taken orally as two 250mg tablets once daily.

  • PlaceboDrug

    Provided as tablets, taken orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) based on Blinded Independent Central Reviewer (BICR) assessment in Grade 1 and Grade 2 participantsTime frame: Up to approximately 31 months

Locations

115 sites in 17 countries. Site status is shown where the registry gives one.

  • Usc Norris Comprehensive Cancer Center

    Los Angeles, California · Terminated

  • Sarcoma Oncology Research Center

    Santa Monica, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Mayo Clinic - Jacksonville, Fl

    Jacksonville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois · Recruiting

  • University of Iowa Hospitals & Clinics- Holden Comprehensive Cancer Center

    Iowa City, Iowa · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic - Rochester, Mn

    Rochester, Minnesota · Recruiting

  • The Washington University

    St Louis, Missouri · Recruiting

  • Nebraska Methodist Hospital

    Omaha, Nebraska · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Oregon Health & Science University Knight Cancer Institute

    Portland, Oregon · Recruiting

  • University of Pittsburgh Medical Center-Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • The Univeristy of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Flinders Medical Centre

    Bedford Park, Australia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, Australia · Not yet recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Australia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • St Vincent'S Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia · Recruiting

  • Cliniques Universitaires St. Luc

    Brussels, Belgium · Recruiting

  • U.Z. Gent

    Ghent, Belgium · Recruiting

  • Centre Multidisciplinaire de Oncologie Medicale

    Liège, Belgium · Recruiting

  • Hospital de Amor - Barretos

    Barretos, Brazil · Recruiting

  • Hospital Das Clínicas Da Ufmg

    Belo Horizonte, Brazil · Recruiting

  • CIONC

    Curitiba, Brazil · Recruiting

  • Cepon - Centro de Pesquisas Oncologicas

    Florianópolis, Brazil · Recruiting

  • Fundação Amaral Carvalho - Jaú/ Sp

    Jaú, Brazil · Recruiting

  • Icesp - Instituto Do Câncer Do Estado de São Paulo

    São Paulo, Brazil · Recruiting

  • Impar Serviços Hospitalares S.A. - Hospital Nove de Julho

    São Paulo, Brazil · Terminated

  • Hospital A C Camargo

    São Paulo, Brazil · Recruiting

  • Hospital Albert Einstein

    São Paulo, Brazil · Recruiting

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.